Biochimica et Biophysica Acta-Reviews on Cancer

Article	Citations
Fibrosis and cancer: A strained relationship	306
Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer	170
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting	166
Cholesterol metabolism: New functions and therapeutic approaches in cancer	159
Advances in clinical immunotherapy for gastric cancer	138
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter	127
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer	117
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics	114
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.	103
Non-coding RNAs and potential therapeutic targeting in cancer	102
Targeting tumor microenvironment in ovarian cancer: Premise and promise	100
The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential	99
Progress and challenges of immunotherapy in triple-negative breast cancer	94
Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside	93
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy	91
Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives	91
Caspase-8: The double-edged sword	86
Cholesterol and beyond - The role of the mevalonate pathway in cancer biology	80
The emerging role of paraptosis in tumor cell biology: Perspectives for cancer prevention and therapy with natural compounds	75
Understanding and advancement in gold nanoparticle targeted photothermal therapy of cancer	72
HER2-targeted therapies in gastric cancer	70
Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy	70
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal	65
Targeting tumor-associated macrophages for cancer immunotherapy	64
The role of N6-methyladenosine mRNA in the tumor microenvironment	63

Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types	62
Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors	55
Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics	54
Genomic instability, inflammatory signaling and response to cancer immunotherapy	54
Tumor-associated neutrophils and neutrophil-targeted cancer therapies	53
New insights on sorafenib resistance in liver cancer with correlation of individualized therapy	53
Metabolic reprogramming in renal cancer: Events of a metabolic disease	53
The RNA m6A writer METTL14 in cancers: Roles, structures, and applications	52
The clinical relevance of gene expression based prognostic signatures in colorectal cancer	51
Pharmacological significance of the non-canonical NF-κB pathway in tumorigenesis	51
Immunotherapy for advanced hepatocellular carcinoma, where are we?	50
Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer	50
PTEN in osteosarcoma: Recent advances and the therapeutic potential	50
Communication in tiny packages: Exosomes as means of tumor-stroma communication	48
Long non-coding RNAs and cancer metastasis: Molecular basis and therapeutic implications	48
HOX genes function in Breast Cancer development	46
Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions	46
The emerging role of miRNA clusters in breast cancer progression	45
Combinatorial therapy in tumor microenvironment: Where do we stand?	45
LOXL2 in cancer: regulation, downstream effectors and novel roles	44
Non-mitotic functions of polo-like kinases in cancer cells	44
Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression	43
Targeting Bcl-2 for cancer therapy	43
SOS GEFs in health and disease	42
The emerging roles of exosomes in anti-cancer drug resistance and tumor progression: An insight towards tumor-microenvironment interaction	41
The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer	41
Nerve input to tumours: Pathophysiological consequences of a dynamic relationship	39
CCR7 as a therapeutic target in Cancer	39
DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer	39
Cyclin-dependent kinases in DNA damage response	38
Classification of extrachromosomal circular DNA with a focus on the role of extrachromosomal DNA (ecDNA) in tumor heterogeneity and progression	38
Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy	38
SOX9: An emerging driving factor from cancer progression to drug resistance	37
Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma	37
Bacteria as a double-action sword in cancer	36
Cancer regeneration: Polyploid cells are the key drivers of tumor progression	35
Cross talk between autophagy and oncogenic signaling pathways and implications for cancer therapy	35
Human MYC G-quadruplex: From discovery to a cancer therapeutic target	35
Emerging roles of HSF1 in cancer: Cellular and molecular episodes	35
Resistin: An inflammatory cytokine with multi-faceted roles in cancer	34
Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer	34
Enzyme-based autophagy in anti-neoplastic management: From molecular mechanisms to clinical therapeutics	34
The role of CAF derived exosomal microRNAs in the tumour microenvironment of melanoma	34
HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential	34
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers	34
MYBL2 amplification in breast cancer: Molecular mechanisms and therapeutic potential	33
Mitochondria: The metabolic switch of cellular oncogenic transformation	33
The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma	33
Pre-clinical tumor models of primary brain tumors: Challenges and opportunities	33
Organoid model: A new hope for pancreatic cancer treatment?	33

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore	33
Recent advances in organoid development and applications in disease modeling	32
Metabolic tricks of cancer cells	31
The outstanding antitumor capacity of CD4+ T helper lymphocytes	31
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions	31
Role of tyrosine phosphorylation in modulating cancer cell metabolism	30
RUNX1 and cancer	30
MCM family in gastrointestinal cancer and other malignancies: From functional characterization to clinical implication	30
Drug resistance in colorectal cancer: An epigenetic overview	29
Closing the translation gap: AI applications in digital pathology	29
Delivery routes matter: Safety and efficacy of intratumoral immunotherapy	29
Role of gut microbiota in epigenetic regulation of colorectal Cancer	29
Nucleic acid nanotechnology for cancer treatment	29
New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies	29
HOX genes and the NF-κB pathway: A convergence of developmental biology, inflammation and cancer biology	29
Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model	29
A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors	28
Modeling pancreatic cancer in mice for experimental therapeutics	28
FOX transcription factor family in hepatocellular carcinoma	28
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer	28
The multifaceted roles of gasdermins in cancer biology and oncologic therapies	27
Odors and cancer: Current status and future directions	27
A “hit-and-run” affair – A possible link for cancer progression in virally driven cancers	27
GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment	27
Pathogenesis and therapeutic strategy in platinum resistance lung cancer	27
The progress of immune checkpoint therapy in primary liver cancer	26
Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission	26
Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing	26
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents	26
EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy	25
Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance	25
Exosomes: The protagonists in the tale of colorectal cancer?	24
DNA damage response inhibitors: An avenue for TNBC treatment	24
EpCAM cellular functions in adhesion and migration, and potential impact on invasion: A critical review	24
Metabolic heterogeneity in cancer: An overview and therapeutic implications	24
P53 in skin cancer: From a master player to a privileged target for prevention and therapy	24
CRISPR screen in mechanism and target discovery for cancer immunotherapy	24
Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy	24
Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles	23
Inhibiting homologous recombination by targeting RAD51 protein	23
Mitochondrial dynamics, a new therapeutic target for Triple Negative Breast Cancer	23
Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology	23
Small nucleolar RNA and its potential role in breast cancer – A comprehensive review	22
Platinum-based systematic therapy in triple-negative breast cancer	22
Epigenetic memory in development and disease: Unraveling the mechanism	22
Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer	22
Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs	22
Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy	22
Immunomodulatory effects of ablation therapy on tumors: Potentials for combination with immunotherapy	22
Colorectal cancer: Metabolic interactions reshape the tumor microenvironment	22
Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression	22
Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?	22
Technologies for targeting DNA methylation modifications: Basic mechanism and potential application in cancer	21
The role of DNA damage and repair in liver cancer	21
The use of nanotechnology to combat liver cancer: Progress and perspectives	21
Multifaceted roles of HSF1 in cell death: A state-of-the-art review	21
New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab	21
Super-enhancers: A new frontier for glioma treatment	20
Targeting EGFR in melanoma – The sea of possibilities to overcome drug resistance	20
Centrosome amplification in cancer and cancer-associated human diseases	20
Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression	20
Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression	20
Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients	20
βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies	20
Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies	20
Mesenchymal stem cells in glioblastoma therapy and progression: How one cell does it all	20
Pericytes cross-talks within the tumor microenvironment	20
Gut mycobiome: A promising target for colorectal cancer	20
PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway	19
Protein phosphatase 1 in tumorigenesis: is it worth a closer look?	19
Role of fibrillin-2 in the control of TGF-β activation in tumor angiogenesis and connective tissue disorders	19
Recent advances in understanding the molecular role of phosphoinositide-specific phospholipase C gamma 1 as an emerging onco-driver and novel therapeutic target in human carcinogenesis	19
The evolution and ecology of benign tumors	19
miRNAs and androgen deprivation therapy for prostate cancer	19
Keep your eyes peeled for long noncoding RNAs: Explaining their boundless role in cancer metastasis, drug resistance, and clinical application	18
Long non-coding RNAs: A view to kill ovarian cancer	18
Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer	18
Balancing neurotrophin pathway and sortilin function: Its role in human disease	18
The role of autophagy in pancreatic cancer progression	18
Ductal metaplasia in pancreas	18

Peptides that immunoactivate the tumor microenvironment	18
Matrix stiffness and its influence on pancreatic diseases	17
Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy	17
Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma	17
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials	17
Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer	17
Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor’s arsenal	17
How to evaluate deep learning for cancer diagnostics – factors and recommendations	17
Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives	16
Designing precision medicine panels for drug refractory cancers targeting cancer stemness traits	16
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors	16
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box	16
Small extracellular vesicles (exosomes) and their cargo in pancreatic cancer: Key roles in the hallmarks of cancer	16
The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation	16
The impact of HPV infection on human glycogen and lipid metabolism – a review	16
Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages	15
The Epigenetic landscape of Circulating tumour cells	15
Emerging roles of the nectin family of cell adhesion molecules in tumour-associated pathways	15
The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients	15
The role of m6A modification in pediatric cancer	15
Diffuse gastric cancer: Emerging mechanisms of tumor initiation and progression	15
Exosomes as Biomarkers of Human and Feline Mammary Tumours; A Comparative Medicine Approach to Unravelling the Aggressiveness of TNBC	15
Oxygen gradient and tumor heterogeneity: The chronicle of a toxic relationship	15
The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors	14
Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer	14
New insights into molecular pathways in colorectal cancer: Adiponectin, interleukin-6 and opioid signaling	14
Emerging functions and clinical prospects of connexins and pannexins in melanoma	14
CXCL13-CXCR5 axis: Regulation in inflammatory diseases and cancer	14
Biosensors as diagnostic tools in clinical applications	14
Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges	14
AMPK: An odyssey of a metabolic regulator, a tumor suppressor, and now a contextual oncogene	14
Extracellular proteolysis in glioblastoma progression and therapeutics	14
Proteomics of post-translational modifications in colorectal cancer: Discovery of new biomarkers	14
Platelet cancer cell interplay as a new therapeutic target	14
In vitro anticancer properties of anthocyanins: A systematic review	14
Unfolding the cascade of SERPINA3: Inflammation to cancer	14
The role of 5-HT metabolism in cancer	13
Application of organoids in translational research of human diseases with a particular focus on gastrointestinal cancers	13
Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs	13
Systematic interaction of plasma albumin with the efficacy of chemotherapeutic drugs	13
Ubiquitination/de-ubiquitination: A promising therapeutic target for PTEN reactivation in cancer	13
Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis	13
Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells	13
To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3	13
Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs	13
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors	13
Unmasking carcinoma-associated fibroblasts: Key transformation player within the tumor microenvironment	13
Odyssey of trefoil factors in cancer: Diagnostic and therapeutic implications	13
Targeting nanoparticles to malignant tumors	13
Regulatory role of Non-canonical DNA Polymorphisms in human genome and their relevance in Cancer	13
Extracellular vesicle-based liquid biopsy holds great promise for the management of ovarian cancer	13
Non-coding RNA-mediated autophagy in cancer: A protumor or antitumor factor?	13
Killing the “BAD”: Challenges for immunotherapy in pancreatic cancer	13
Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors	12
Power and promise of exosomes as clinical biomarkers and therapeutic vectors for liquid biopsy and cancer control	12
ANTs and cancer: Emerging pathogenesis, mechanisms, and perspectives	12
Intestinal multicellular organoids to study colorectal cancer	12
Psychological intervention to treat distress: An emerging frontier in cancer prevention and therapy	12
Machine Learning in Epigenomics: Insights into Cancer Biology and Medicine	12
PERP-ing into diverse mechanisms of cancer pathogenesis: Regulation and role of the p53/p63 effector PERP	12
Mucin expression, epigenetic regulation and patient survival: A toolkit of prognostic biomarkers in epithelial cancers	12
PDLIM2: Signaling pathways and functions in cancer suppression and host immunity	12
Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies	12
Can EGFR be a therapeutic target in breast cancer?	12
The intratumoural microbiota in cancer: new insights from inside	12
Consequence of distinctive expression of MUC2 in colorectal cancers: How much is actually bad?	12
Organ-on-Chip platforms to study tumor evolution and chemosensitivity	12
Two decades of a protooncogene HPIP/PBXIP1: Uncovering the tale from germ cell to cancer	12
ETV6 gene aberrations in non-haematological malignancies: A review highlighting ETV6 associated fusion genes in solid tumors	12
Role of exosomes in lung cancer: A comprehensive insight from immunomodulation to theragnostic applications	12
The interaction of SET and protein phosphatase 2A as target for cancer therapy	12
Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives	11
Protein glycosylation in head and neck cancers: From diagnosis to treatment	11
Potential diagnostic and therapeutic roles of exosomes in pancreatic cancer	11
Interstitial fluid pressure as an emerging biomarker in solid tumors	11
Obscurin: A multitasking giant in the fight against cancer	11
A synopsis of modern - day colorectal cancer: Where we stand	11
Combination of microtubule targeting agents with other antineoplastics for cancer treatment	11
CD47: Beyond an immune checkpoint in cancer treatment	11
Clinicopathologic features and treatment advances in cancers with HER2 alterations	11
Drug tolerance to target therapy in melanoma revealed at single cell level: What next?	11
Role of the calcium-sensing receptor (CaSR) in cancer metastasis to bone: Identifying a potential therapeutic target	11
Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer	11
The methyltransferase SETD3-mediated histidine methylation: Biological functions and potential implications in cancers	11
The emerging roles of dual-specificity phosphatases and their specific characteristics in human cancer	11
Targeting Cdc20 for cancer therapy	11
The roles of small extracellular vesicles in lung cancer: Molecular pathology, mechanisms, diagnostics, and therapeutics	11
Role of the constitutive androstane receptor (CAR) in human liver cancer	10
Control of tumor angiogenesis and metastasis through modulation of cell redox state	10
The O-GlcNAcylation and its promotion to hepatocellular carcinoma	10
Proteomics and metabolomics approach in adult and pediatric glioma diagnostics	10
Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy	10
Ezrin gone rogue in cancer progression and metastasis: An enticing therapeutic target	10
The signaling pathways regulated by KRAB zinc-finger proteins in cancer	10
The potential roles of p53 signaling reactivation in pancreatic cancer therapy	10